Market revenue in 2020 | USD 4,335.0 million |
Market revenue in 2028 | USD 7,374.6 million |
Growth rate | 6.9% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | Neurodegenerative Diseases |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 45.6% in 2020. Horizon Databook has segmented the France central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
Central nervous system diseases, such as Alzheimer’s, Parkinson’s, epilepsy, stroke, and multiple sclerosis are the most common type of neurodegenerative diseases in France. The French government has had three successive plans for Alzheimer’s since the year 2000, having concluded in 2019.
They prioritized early diagnosis of Alzheimer’s and have been extended, with a roadmap focused on a few priorities along with patient associations. The rapidly aging French population is expected to impel incidence of Alzheimer’s in the country over the forecast period, driving market growth.
However, the 2018 decree published by the French Ministry of Health removed some of the Alzheimer’s drugs, such as donepezil, rivastigmine, galantamine, & memantine, from the list of reimbursed drugs, which is likely to impede growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into France central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account